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Abstract
After a non-inferiority clinical trial, a new therapy may be accepted as
effective, even if its treatment effect is slightly smaller than the current stan-
dard. It is therefore possible that, after a series of trials where the new therapy
is slightly worse than the preceding drugs, an ineffective or harmful therapy
might be incorrectly declared efficacious; this is known as “bio-creep.” Several
factors may influence the rate at which bio-creep occurs, including the distri-
bution of the effects of the new agents being tested and how that changes
over time, the choice of active comparator, the method used to model the
variability of the estimate of the effect of the active comparator, and changes
in the effect of the active comparator from one trial to the next (violations
of the constancy assumption). We performed a simulation study to examine
which of these factors might lead to bio-creep and found that bio-creep was
rare, except when the constancy assumption was violated.
1 Introduction
When a therapy exists that has been proven to reduce the rate of mortality or ma-
jor morbidity for a given condition, it is generally considered unethical to withhold
this treatment from subjects as would happen in a placebo-controlled clinical trial.
In these settings, then, investigational treatments are frequently tested against an
active comparator. For registrational purposes, these new therapies are often not
required to be more efficacious than other treatments on the market; they must
merely be shown to have a positive treatment effect. Especially if an investigational
treatment has advantages over the standard therapy, such as an easier mechanism of
1Corresponding author:
Siobhan Everson-Stewart
Department of Biostatistics, Box 357232
University of Washington
Seattle, WA 98195-7232
e-mail: spes@uw.edu
Tel: +1-206-616-0463
Fax: +1-206-543-0131
This research was supported in part by the NHLBI through training grant T32 HL007183
to the University of Washington. Hosted by The Berkeley Electronic Press
Bio-Creep in Non-Inferiority Clinical Trials 2
delivery or an improved safety profile, some reduction in efficacy may be clinically
acceptable. A clinical trial designed to demonstrate that the difference in the treat-
ment effects of the investigational therapy and active comparator is within such an
acceptable margin is called a non-inferiority clinical trial. However, this raises the
concern that if each new therapy is perhaps slightly worse than the preceding drugs,
after a series of non-inferiority trials, an ineffective or harmful therapy may falsely
be deemed efficacious, a phenomenon known as “bio-creep” [1, 2].
Bio-creep has previously been mentioned as a theoretical possibility, but little
exploration has been done to discover if and when it might occur in practice. In
order to address these issues, we designed a simulation study to investigate what
factors contribute to the occurrence of bio-creep, and to quantify how frequently it
may be happening. There are several factors we believed may influence how often
bio-creep occurs, including the true efficacy of the new therapies being tested, how
the effect of a single drug changes from trial to trial, and the characteristics of the
trials themselves. These traits can be loosely grouped into those describing the
clinical setting in which the trial is being performed, such as the distribution of
the effects of new therapies, and those related to trial methodology. In addition to
exploring when bio-creep occurs, we also strove to describe how the situations where
bio-creep occurred differed from those where it did not.
2 Defining Non-Inferiority
The definition of non-inferiority in any trial has two major components: the non-
inferiority margin and the statistic being used. The non-inferiority margin can be
thought of as the amount by which the true effect of the new therapy is allowed to
be worse than that of the active control: when we can, with a reasonable degree of
certainty, establish that the effect of the new therapy is not worse than this threshold,
we consider it to be acceptably effective. This quantity is normally specified in the
parameter space (i.e., in terms of the true effect of the treatment relative to the
active control). This, along with information from the historical trials, intrinsically
defines a corresponding margin in the sample space (i.e. the observed effect that
would be declared as acceptably non-inferior). The choice of method used to combine
the information from historical trials of the active comparator with that from the
new trial is not as clinically interpretable as is the margin, but still importantly
influences many of the operational characteristics of a trial.
2.1 Choosing the Non-Inferiority Margin
One of the greatest challenges of planning a non-inferiority clinical trial is selecting
the non-inferiority margin. The ICH E-9 states that the non-inferiority margin
should be the “largest difference that can be judged to be clinically acceptable, and
should be smaller than the differences observed in superiority trials of the active
comparator [3].” When setting the margin, one must consider the clinical significance
of the specified decrease in efficacy, as well as what is known of the effect of active
comparator. It is important that the non-inferiority margin not exceed the effect
http://biostats.bepress.com/uwbiostat/paper359
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of the active comparator, or else a treatment known to be ineffective would be
considered “non-inferior” by definition.
This margin may be set on either an absolute or a relative scale. In the first case,
one may demand that the effect of the new therapy as compared to placebo exceed
some threshold (e.g. hazard ratio on placebo compared to experimental therapy
must exceed 1.1), often chosen to be the minimally clinically important difference.
In the second, the margin is defined relative to the efficacy of the active control;
the experimental treatment must retain some percentage of the effect of the active
comparator. As long as the active comparator retains some effect, using a relative
margin ensures that an approved therapy must deliver some benefit. It is possible,
however, for a new therapy to preserve the pre-specified percentage while falling
below an absolute threshold defining the minimally clinically important difference.
Selecting a relative non-inferiority margin can be viewed not only as a way of
ensuring that the efficacy of the investigational agent is acceptably close to that of
the active control, but also as a tool to “discount” the effect of the active control
in the current trial relative to its historical effect [4]. In their 2003 article, Wang
and Hung express such a sentiment: “In order to be fairly certain that the new drug
would have been superior to placebo had the placebo treatment been studied in the
trial, it was decided that the new drug must be shown to preserve at least 50% of
the control effect in this target population of the active-controlled trial [5].”
One can also use concerns about patient safety to argue for demanding that a
certain percentage of the effect of the active control is retained. While, strictly
speaking, efficacy requirements demand only that a new treatment be more effective
than placebo, safety must also be considered. The full safety profile of a new therapy
is seldom known at the time it is approved, and those receiving such treatment during
a clinical trial are being exposed to unknown risks. In light of this uncertainty, it
seems prudent to demand that a new treatment not be meaningfully worse than an
existing treatment, as it would not be ethical to expose patients to a new treatment
with an unknown safety profile if it is markedly worse than their existing choices.
Demanding 50% retention of the effect of the active comparator, with the hope of
actually preserving this fraction of the efficacy, is one way of ensuring that is not the
case. Additionally, doing so also allows one to infer efficacy of the new treatment
as compared to placebo, even if the effect of the active control is markedly reduced
from what was observed historically [6, 7, 8].
2.2 Incorporating Uncertainty
It is important to incorporate the uncertainty associated with estimating the effect
of the active comparator when selecting the statistical methods to be used, especially
if the non-inferiority margin is defined as a proportion of the effect of that therapy
estimated from historical data. Many available methods do take this increased
variability into account, though their operating characteristics vary widely [9, 10].
For the purpose of this study, we used a more direct approach based on a putative
placebo, sometimes known as a “synthesis” method [10, 11].
Another commonly used method is the 95-95 rule [12]. In this case, the non-
inferiority margin is set at the lower bound of a 95% confidence interval for the
Hosted by The Berkeley Electronic Press
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efficacy of the active control (as compared to placebo). As long as the 95% confidence
interval for the effect of the experimental therapy (as compared to the active control)
lies above this margin, the experimental therapy is declared non-inferior. If one
wants to retain a fraction of the effect of the active comparator, say X ∗ 100%, then
the margin is set at X times the lower bound of the confidence interval for the effect
of the active comparator. This method is known to be conservative when the true
effect of the active control is constant across trials [10].
2.3 Notation
If one believes that historical trials of the active comparator versus a placebo accu-
rately estimate the expected efficacy of the active comparator in the new trial, it is
very straightforward to estimate the efficacy of the experimental agent transitively
(this is the aforementioned synthesis method). The estimate would be based on the
information we have on three groups of subjects: the placebo group, denoted P ; the
group receiving the active comparator, or standard therapy, S; and those receiving
the new treatment, N . In a proportional hazards model of a time-to-event analysis,
we have λP (t) = λS(t) exp(θSP ). Under this model, θSP is the log hazard ratio of the
placebo group compared to the active treatment group, and we assume without loss
of generality that θSP > 0 implies that the standard therapy is efficacious. Although
θNP is not directly estimable from a non-inferiority trial, combining the historical
data with the data from the new trial gives us θˆNP = θˆNS + θˆSP . Inference about
the efficacy of the new agent could then be based directly on θˆNP .
In the case where we suspect that the historical trial may not be directly relevant,
we may be able to guard against a loss of efficacy by requiring that the investigational
treatment retain a set percentage of the effect of the active control. This provides
protection against a diminished effect of the active comparator, as long as that
treatment is neither ineffective nor harmful in the subpopulation enrolled in the
trial. For these simulations, we took this approach, with an arbitrary 50% retention
threshold. In practice, this threshold should additionally take into account both the
clinical setting and considerations of patient safety.
Our definition of non-inferiority is equivalent to testing θNP >
1
2
θSP , where θNP
is the log hazard ratio of the experimental treatment group compared to the placebo
group. We want to show:
θNP = θNS + θSP >
1
2
θSP
or, equivalently,
τ ≡ θNS + 1
2
θSP > 0.
If a 95% confidence interval for τ lies entirely above 0, then non-inferiority can
be concluded with a nominal one-sided 0.025 Type I error rate. Since V ar(τ) =
σ2NS +
1
4
σ2SP , this confidence interval can be easily constructed using estimates from
historical trials of the active comparator as well as the data from the current trial.
http://biostats.bepress.com/uwbiostat/paper359
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2.3.1 Example
As an example, consider the case of second-line chemotherapy in non-small-cell
lung cancer. Docetaxel was established as effective in a placebo-controlled clini-
cal trial [13]. Later, when pemetrexed was tested in this same indication, a non-
inferiority trial was performed comparing pemetrexed to docetaxel [14]. From the
earlier trial, we have exp
(
θˆSP
)
= 1.78, with a 95% confidence interval of 1.14 to
2.86 [14]. Considering this historical data, what non-inferiority margin should be
used? If we can establish that exp (θNS) >
1
1.78
= 0.56, it suggests that pemetrexed
is more effective than placebo. However, the variability in the estimate of θSP must
be taken into consideration. Additionally, we may want to demand that pemetrexed
retain some portion of the effect of docetaxel before declaring non-inferiority. If
we choose to use a synthesis method to account for the variability of θˆSP while
demanding 50% retention, we want to be confident that
τ ≡ θNS + 1
2
θSP > 0.
We obtain θˆSP = log (1.78) and σˆSP = 0.23 from the historical data. Since the
trial comparing docetaxel to pemetrexed was designed to stop when n = 400 events
had been observed, we know that σ2NS ≈ 4400 = 0.01. We can then calculate that
pemetrexed will be declared non-inferior to docetaxel when exp
(
θˆNS
)
≥ 1.01, with
a corresponding confidence interval of (0.83, 1.23). In this setting, using a synthesis
method with 50% retention implies a margin of 0.83 on the exp (θNS) scale.
Alternatively, a 95-95 rule could be utilized. If the aim of the study is to de-
termine that pemetrexed would have been show to be superior to placebo had one
been included, then the margin would be 1
1.14
= 0.88. We can also incorporate
a demand for 50% retention while using this 95-95 method, yielding a margin of√
(0.88) = 0.94 for exp (θNS). With the trial designed to stop when 400 events had
been observed, this lower bound would only be exceeded when exp
(
θˆNS
)
> 1.14.
3 Methods: A Simulation Study
We hoped to identify which factors can lead to increases in the rate of bio-creep.
1. We began by considering how bio-creep is affected by the distribution from
which the effects of new agents are drawn. Naturally, if all agents tested in
trials are effective, bio-creep will never occur.
2. The changes in the effect of a single therapy across trials are also of great
importance. Most non-inferiority methodology assumes that the treatment
of any one drug is constant across trials; this is known as the “constancy
assumption” [9, 12, 15]. We examined how violations of this assumption affect
bio-creep. These changes in the efficacy of a therapeutic agent over time may
result from variation in patient characteristics from one study to the next,
differences in ancillary treatment, or other changes in the clinical setting. WeHosted by The Berkeley Electronic Press
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chose to imagine that all drugs are effective in one sub-population, called
“susceptibles” here, and ineffective in the remainder of the population. We
modeled this proportion as random, and then as steadily decreasing.
3. We also thought the way that distribution of the efficacy of new therapies
changes across a series of trials could influence bio-creep, so we looked to see
the consequences of allowing that distribution to shift over time.
4. We additionally examined two different methods for modeling the variance in
θˆSP : ignoring it completely and accounting for in with the synthesis method.
By doing so, we hoped to identify how much harm could be done by mis-
specifying the variability of θNP .
5. Finally, we looked at two different methods for selecting the active control in
the current trial. Our first approach was to select the previously approved ther-
apy with the highest estimated treatment effect; in the second, we selected the
active control that gave an ineffective new treatment the highest probability
of being approved.
In each repetition of the study, 11 clinical trials were simulated: one of a new
therapy against placebo and 10 non-inferiority trials of new agents against an active
comparator. Every trial contained 500 subjects on both treatment arms. A time-
to-event analysis was used, with event and censoring times generated using the
exponential distribution. The baseline (placebo group) event rate was set at 0.25
per year; all groups had a censoring rate of 0.1 per year. A trial ended when 100,
376, or 500 events had been observed.
In the first, placebo-controlled trial, the true treatment effect of the experimental
therapy, θNP , was log(1.5) = 0.405. The simulated data was used to estimate this
treatment effect, as well as its variance. After the conclusion of this first trial, the
experimental treatment became the new standard treatment and was used as the
active comparator in the next trial. For this second trial, we imagined investigators
selected a new experimental therapy from a population of treatments. Data for this
second trial was simulated, and the results combined with those of the first trial to
estimate τ as above. If the confidence interval for τ was entirely positive, then the
new treatment was declared non-inferior to the active control. If, additionally, θˆNP >
θˆSP , then in some simulations the new treatment became the standard therapy, and
was used as the active comparator in the next trial. In this case, the new estimate
of the treatment effect of the standard versus the placebo is θˆ∗SP = θˆNP = θˆNS + θˆSP
and the estimated variance σˆ2∗SP = σˆ
2
NP = σˆ
2
NS + σˆ
2
SP . Subsequent trials proceed as
the second trial, with a randomly generated experimental therapy compared to the
treatment considered the standard at the time. For each combination of parameters,
1000 repetitions were performed;
3.1 Study 1: Distribution of the Treatment Effect of New
Agents
We modeled the true effect of the treatments being tested in the non-inferiority trials
using a normal distribution with a mean of 0.405, 0.305, or 0.155, corresponding tohttp://biostats.bepress.com/uwbiostat/paper359
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hazard ratios of 1.5, 1.36, and 1.17 respectively, and a standard deviation of 0.05,
0.10, or 0.50. These nine different combinations were selected in an attempt to
mimic different scenarios that might occur in drug development. Centering the
distribution of new drugs at the same point as the first approved therapy may
approximate the scenario where companies attempt to develop a therapy similar
to one their competitors are marketing. Similarly, by centering the distribution at
a point slightly lower than the first drug, we hope to mimic the case where, by
modifying an existing molecule in an attempt to reduce its side-effects, the efficacy
is slightly reduced as well. The lowest of the means represents a more pessimistic
view of drug development.
3.2 Study 2: Violations of the Constancy Assumption
To model possible treatment effect variation, we repeated the simulation study in a
population where all therapies were effective in a proportion of the population and
had no effect in the rest. As this proportion changed from trial to trial, the true
effect of any given product, averaged over the study population, changed as well.
One can easily imagine a series of trials of agents in a class, where some patients
benefit from any of the drugs in the class, but for others the therapies are ineffective.
The susceptible proportion was generated in two different ways. First, for each
trial, this proportion was randomly generated from a Beta(10,3) distribution; this
distribution give treatment-susceptible percentages between 56.1% and 92.8% in 95%
of the trials, with a mean of 76.9%. This corresponds to a situation where each trial
draws from a single population of interest; differences in treatment effect are purely
random. We also considered the case where the susceptible proportion declined
steadily from one trial to the next, corresponding to a situation where susceptible
patients are no longer interested in participating in research, as they have found a
therapy effective for them. In this situation, the susceptible proportion started at
0.95 in the first trial, and declined in intervals of 0.05 to 0.45 in the final trial in
each sequence. In both cases, the rest of the simulation proceeded as before.
3.3 Study 3: Choice of active comparator
While changing the susceptible proportion from trial to trial may increase the oc-
currence of bio-creep, many other trial characteristics affect the rate at which it
occurs as well. First, we wanted to see how the choice of active comparator influ-
enced bio-creep. We compared two different strategies: in the first, we used the
approved therapy with the highest estimated efficacy as the active comparator, as
in the first two studies; in the second, we used the approved drug that gave an
ineffective therapy (θNP = 0) the highest probability of being approved.
In order to select the standard that will make it “easiest” for an ineffective
therapy to be approved, we need
Pr
[
θˆNS +
1
2
θˆSP − 1.96
√
σˆ2NS +
1
4
σ2SP > 0
∣∣∣ θNP = 0, θˆSP , σˆ2SP
]
. (1)
Hosted by The Berkeley Electronic Press
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for any potential standard. By noting that in this case θˆNS ∼ N(−θSP , σ2NS) and
θˆSP = θSP + bSP + SP , where bSP is the bias of θˆSP and SP ∼ N(0, σ2SP ), and
estimating σ2NS with
4
n
, we can express this probability as∫ ∞
−∞
∫ ∞
√
4
n
(
1
2
θˆSP−bSP−SP+1.96
√
4
n
+ 1
4
σˆ2SP
) 1
σˆSP
φ (x)φ
(
SP
σˆSP
)
dx dSP
After estimating bSP by simulation, (1) was calculated for each potential active
comparator; the approved therapy that maximizes this probability was then cho-
sen as the new active control. This was done in the setting where the constancy
assumption held.
3.4 Study 4: Modeling of variability
We next examined the choice of variance model. We compared using a synthesis
method approach that appropriately modeled the variance in the estimated effect of
the active comparator, as above, to one where the variability of the estimate of the
active control was ignored.
3.5 Study 5: Trends in treatment effect
Finally, we looked at shifts in the distribution of θNP over time. In distinction
from the first two factors examined, this is a characteristic of the study setting, and
cannot be controlled by investigators. We compared the case where the distribution
of new therapies centered at 0.405, 0.305, or 0.115, to that when it was instead
centered around θSP , θSP − 0.10, or θSP − 0.25. These two factors were examined in
the context where the proportion of “susceptible” subjects decreases steadily over
time, with each trial stopped when 100 events had been observed.
4 Results
4.1 Study 1: Distribution of the Treatment Effect of New
Agents
Several aspects of the distribution of the treatment effects of new agents influence the
rate with which bio-creep occurs. As expected, when the mean of the distribution is
lower, the rate of bio-creep increases. Perhaps counter-intuitively, however, the rate
of bio-creep is highest at intermediate levels of variance. Additionally, increasing
sample size also reduces the incidence of bio-creep.
Each simulation setting yields detailed information about the behavior of a series
of non-inferiority trials. The case where mean(θNP )= 0.305, SD(θNP )= 0.10, and
with 100 events will be reviewed in detail, and then a summary of the other settings
will be provided. For this combination of trial parameters, an average of 3.25 prod-
ucts were approved for market after the series of 11 trials. The true hazard ratio of
placebo as compared to a newly approved product ranged from 1.07 to 1.94. Table 1
gives the quantiles of the true effects of each newly approved product, by the numberhttp:// iostats.bepress.com/uwbiostat/paper359
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of approved products, for the second through seventh products approved; the first
product approved has a hazard ratio of 1.5 by design, and eight or more products
were approved for marketing in so few replications as to make those summaries un-
reliable. First, it should be noted that about 95% of the products approved truly
are “non-inferior” to the first approved product - that is, they preserved at least
50% of the treatment effect, corresponding to a HR of 1.22 or greater. Secondly,
while no approved products were harmful, several had negligible treatment effects.
Interestingly, the distribution of the approved products did not appear to change
over time but remained relatively constant over the course of all of the trials.
An average of 3.0 new standards were adopted per sequence of trials. Since this
is only marginally fewer than the number approved, it was rare that a product was
approved for market and was not adopted as the new standard. Figure 1 shows
the effect of the standard therapy over the 11 trials for the first 10 repetitions of
the simulation for this case where mean(θNP )= 0.305, SD(θNP )= 0.10, and 100
events were observed. This figure illustrates that for some repetitions, the standard
is constant over the duration of all trials; for other repetitions, the effect of the
standard changes frequently. When the effect of the standard changes, rather than
being monotone, those changes tend to oscillate between increases and decreases in
efficacy. The distribution of the standard treatment at the end of trials 2 through 11
is presented in Table 2. Overall, the positive predictive value of the non-inferiority
test was 96.4%, the negative predictive value was 78.8%, and the type-I error rate
was 0.053, double the nominal value. No harmful treatments (HR<1) were approved
for marketing, and ineffective treatments, defined as those with a hazard ratio of
1.10 or less, were approved in only 0.6% of the repetitions.
An overview of the results from Study 1, where the effect of each drug was con-
stant over time, is given in Table 3. Each rate is the percentage of repetitions of the
simulation in which a harmful or ineffective product was approved, not the percent-
age of approved treatments that were harmful or ineffective. Overall, harmful or
ineffective products were approved in relatively few series of trials. Not surprisingly,
the rate increased as the average efficacy of the products being tested decreased.
Bio-creep also occurred more frequently in the lower-powered trials.
Figure 2 shows the median, central 50%, and central 90% of the effects of all
approved therapies at the conclusion of each trial for the cases where n = 100.
Notably, when SD(θNP ) = 0.5 and hence products much superior to the initial
therapy are being tested, the distribution of approved therapies shifts toward more
beneficial drugs.
4.2 Study 2: Violations of the Constancy Assumption
We also wanted to see how often bio-creep occurred when the constancy assump-
tion was violated. We first considered a violation of this assumption due to random
changes in the proportion “susceptible” to the class of agents being tested. Table 4
gives the results from this simulation, where the effect of a single drug in the study
population changed from trial to trial. Here, not surprisingly, bio-creep occurred
much more frequently. For some of the treatment effect distributions, harmful prod-
ucts were approved in more than 3% of repetitions, a clearly unacceptable level of
Hosted by The Berkeley Electronic Press
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error.
We next examined the rates of bio-creep that occur when the proportion of
“susceptible” subjects decreases steadily over time. These results are presented
in Table 5. Here, the rates of bio-creep are even higher than in the above sub-
study, with ineffective products approved in up to 16.3% of repetitions and harmful
products in as many as 4.9%. Interestingly, increasing sample size does not offer the
same protection as before. While the rates of bio-creep did decrease with increasing
sample size for all parameter settings, event with 500 events, as many as 10.2% of
repetitions saw ineffective therapies approved.
4.3 What goes wrong?
We examined the characteristics of the repetitions where ineffective or harmful ther-
apies were approved, and compared them to the repetitions where this did not occur.
Hopefully, identifying the traits that led to this bio-creep can help us develop ways
of preventing it in the future. This was done in the context of Study 2, where the
class of the agents under study decreases steadily over time; we present detailed
results for the case where mean(θNP ) = 0.305, SD(θNP ) = 0.10, and each trial was
stopped when 100 events had been observed.
As can be seen in Table 5, ineffective therapies were approved in 1.9% of rep-
etitions, and harmful therapies in 0.2%. No more than one harmful or ineffective
therapy was approved in any one repetition; on average, 0.32% of approved therapies
were ineffective, and 0.02% were harmful.
Ineffective and harmful therapies were more likely to be approved in repetitions
with many approved therapies and standards. In repetitions where no ineffective
therapies were approved, a mean of 3.6 treatments were on the market, with an
average of 3.2 standards. In contrast, in repetition with ineffective therapies were
approved, the mean number of treatments available was 6.9, with a mean of 5.7 stan-
dards. The contrast is even more striking when examining the repetitions where a
harmful therapy was approved: there, the mean number of approved treatments was
8.5, with an average of 6.0 standards. Of course, those numbers are not be estimated
very precisely, since harmful therapies were approved in just 2/1000 repetitions. In
all of these repetitions, harmful and ineffective therapies were not approved until
later in the chain of trials. The two harmful therapies appeared in trials 8 and 11.
The first ineffective therapy was approved in a trial 5, and the mode (7/19) was at
trial 11. The median trial number where the first ineffective therapy was observed
was 9.
It is noteworthy that the mean estimated effect of the first treatment was much
larger (-0.658) in repetitions that eventually led to the approval of ineffective ther-
apies than in those that did not (-0.553), and even higher in those that yielded a
harmful therapy (mean=-0.772). It seems that when the efficacy of the first therapy,
the “anchor” to the chain of non-inferiority trials, is over-estimated, it is much easier
for new therapies to be approved, including those that are ineffective and harmful.
http://biostats.bepress.com/uwbiostat/paper359
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4.4 Study 3: Choice of active comparator
We began by examining the strategy used to selecting the active comparator. First,
we used the approved therapy with the highest estimated efficacy as the active
comparator. For the next set of simulations, we selected the therapy that, if it
was chosen as the new standard, would result in the highest chance of a completely
ineffective therapy (θNP = 0) being approved. This was done in the setting where
constancy holds. In Table 6, these results are denoted by the columns marked
“Best” and “Easiest”. The rates of approval of ineffective and harmful therapies
are similar for the two procedures, suggesting that it is difficult to chose the active
comparator in a way that “games” the system. The active comparator that provides
the easiest path to approval would have low θSP , high bSP , and low σ
2
SP . With θSP
unknown, however, those factors can’t be optimized simultaneously. High values of
θˆSP can suggest both high θSP and high bSP ; therapies approved later in a chain
of non-inferiority trials will have both high bSP and high σ
2
SP . With these factors
off-setting one another, the method used for selecting the active control does not
appear to greatly affect the rates of bio-creep.
4.5 Study 4: Modeling of variability
We next examined the choice of variance model. We compared a synthesis method
approach to one where the variability of the estimate of the active control was
ignored. This was done when the “susceptible” proportion of the study population
decreases steadily from trial to trial. As expected, using the incorrect variance
model led to disastrous results, as can be seen in the first two columns of Table 7.
In the worst case setting, ineffective therapies were approved in as many as 48% of
repetitions, and harmful therapies in 36%.
4.6 Study 5: Trends in treatment effect
Finally, we wanted to see how changes in the distribution of θNP over time would
affect the rates of bio-creep. When we allowed this distribution to change over
time, θN was centered around either θSP , θSP − 0.10, or θSP − 0.25, rather than
0.405, 0.305, or 0.115. Again, the “susceptible” proportion of the study population
decreased steadily from trial to trial. Results are given in Table 7 for the cases
when the variance model is correct or incorrect. Allowing the distribution of θNP to
change over time affected the bio-creep rates differently, depending on the variance
in the distribution of θNP . At the highest standard deviation studied, 0.50, shifting
the mean of θNP reduced the rates of bio-creep. At the other two variance levels,
however, shifting the mean increased the rate of bio-creep, sometimes drastically.
For example, when mean(θNP ) = 0.305 and SD(θNP ) = 0.05, when ignoring the
variability of θSP , but with a fixed mean of the distribution of θNP , no ineffective
therapies were approved. When the mean shifted over time, ineffective therapies were
approved in 44% of the repetitions. Even when the variance model was correctly
specified, ineffective therapies were approved in 23% of the repetitions.
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5 Discussion
These results demonstrate what should be inherently apparent: it is imperative
to use methodology appropriate for the non-inferiority setting when conducting a
non-inferiority clinical trial. The variability inherent to estimating the effect of the
active comparator must be considered and accounted for; failing to do so results in
disastrously high rates of bio-creep.
Additional thought should be given to selecting the active comparator. We ex-
amined how this choice affected the rates of bio-creep for two different strategies:
using the therapy with the best estimated treatment effect and that giving an in-
effective therapy the highest chance of being approved. Naturally, there are many
other possibility procedures that could be used. For example, a drug developer may
think that its new product stands the best chance against the approved drug with
the lowest estimated treatment effect. Of course, this will lead to a tighter margin
than using a therapy with a higher estimated effect. For the purpose of this sim-
ulation study, we adopted a fixed policy for the selection of the active control. In
reality, this decision should be made only after a careful evaluation of the available
therapies. The estimated effects of the available treatments, and how those effects
have appeared over time, need to be considered along with clinical practice. There
may be ethical issue to entertain as well: are any of the available therapies known
to be superior to the others? It may not be ethical to deny subjects such a therapy.
The evidence supporting the efficacy of the active comparator must also be eval-
uated. Since the first, placebo-controlled trial anchors the chain of non-inferiority
trials which follow, any problems with this first trial can lead to trouble later. If
the effect of that first approved drug just beats placebo, doing a trial with 50%
retention is tantamount to performing a superiority trial. Spuriously high estimates
of the effect of that first therapy greatly increase the chance of an ineffective or
harmful treatment being approved in subsequent trials.
We examined the factors influencing and the rates of bio-creep using one defi-
nition of non-inferiority. Clearly, selecting a higher percentage retention will lead
to lower rates of bio-creep, with a corresponding loss of power to approve beneficial
therapies. Or one may instead be interested in the rates of bio-creep seen using a
fixed margin. We expect the results to be similar to what we observed, with some
variation depending on the population from which new treatment effects are gen-
erated. Other statistics could be used instead of the synthesis method approach
utilized here. For example, we would expect a 95-95 approach, with its built in
conservatism, to result in lower rates of bio-creep, again at the cost of a reduction
in power.
From the above results, it is apparent that violations of the constancy assump-
tion are the largest potential source of bio-creep. When this assumption holds, as
long as appropriate analysis techniques are used in conjunction with a reasonable
non-inferiority margin, bio-creep appears to be rare (at least in settings of our sim-
ulations). However, when this assumption is violated, rates of bio-creep can be
disturbingly high, even when proper methodology is used. Since this assumption
is largely untested (some might even say untestable), these results are quite con-
cerning. Further consideration should be given to techniques for identifying these
http://biostats.bepress.com/uwbiostat/paper359
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violations, and methods for handling them when they are detected.
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Number of
Approved 5th 25th 75th 95th
Products Min. %-tile %-tile Median %-tile %-tile Max.
2 1.07 1.27 1.37 1.46 1.54 1.70 1.94
3 1.12 1.23 1.34 1.42 1.51 1.65 1.85
4 1.03 1.19 1.32 1.41 1.50 1.64 1.82
5 1.12 1.20 1.32 1.40 1.51 1.65 1.92
6 1.11 1.19 1.30 1.39 1.50 1.63 1.82
7 1.09 1.19 1.33 1.38 1.48 1.63 1.79
Table 1: True effects of products on market by number approved from simulation
where mean(θNP ) = 0.305, SD(θNP ) = 0.10, and 100 events were observed.
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Figure 1: Plot of the effect of the standard at the end of each trial, for the first 10
repetitions of the simulation. Parameters set to mean(θˆNP ) = 0.305, SD(θˆNP ) =
0.10, and 100 observed events.
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Number of
Approved 5th 25th 75th 95th
Products Min. %-tile %-tile Median %-tile %-tile Max.
2 1.19 1.46 1.50 1.50 1.50 1.50 1.76
3 1.07 1.38 1.50 1.50 1.50 1.59 1.94
4 1.13 1.32 1.50 1.50 1.50 1.62 1.94
5 1.13 1.33 1.50 1.50 1.50 1.64 1.94
6 1.05 1.32 1.48 1.50 1.50 1.66 1.94
7 1.03 1.32 1.46 1.50 1.50 1.67 1.94
8 1.12 1.30 1.44 1.50 1.50 1.67 1.94
9 1.09 1.30 1.44 1.50 1.52 1.69 1.94
10 1.10 1.28 1.43 1.50 1.52 1.69 1.94
11 1.12 1.29 1.43 1.50 1.54 1.70 1.94
Table 2: True effects of standard therapy at the conclusion of each trial, from sim-
ulation where mean(θNP ) = 0.305, SD(θNP ) = 0.10, and 100 events were observed.
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mean(θNP ) SD(θNP ) n=100 n=376 n=500
0.405 0.05 % Ineffective 0 0 0
% Harmful 0 0 0
0.305 0.05 % Ineffective 0 0 0
% Harmful 0 0 0
0.155 0.05 % Ineffective 4.5 1.5 0.9
% Harmful 0 0 0
0.405 0.10 % Ineffective 0 0 0
% Harmful 0 0 0
0.305 0.10 % Ineffective 0.6 0 0
% Harmful 0 0 0
0.155 0.10 % Ineffective 6.0 2.3 1.0
% Harmful 1.0 0.3 0.1
0.405 0.50 % Ineffective 0.6 0 0
% Harmful 0.3 0 0
0.305 0.50 % Ineffective 0.5 0 0
% Harmful 0.1 0 0
0.155 0.50 % Ineffective 1.1 0 0
% Harmful 0.3 0 0
Table 3: Results from Study 1.
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Figure 2: Median, central 50% and central 90% of approved therapies over time.
Each trial had 100 observed events.
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mean(θNP ) SD(θNP ) n=100 n=376 n=500
0.405 0.05 % Ineffective 0 0 0
% Harmful 0 0 0
0.305 0.05 % Ineffective 0 0 0
% Harmful 0 0 0
0.155 0.05 % Ineffective 8.9 2.8 2.2
% Harmful 0.2 0 0
0.405 0.10 % Ineffective 0.2 0 0
% Harmful 0 0 0
0.305 0.10 % Ineffective 1.4 0.3 0.4
% Harmful 0 0 0
0.155 0.10 % Ineffective 13.3 3.4 3.5
% Harmful 3.1 0.5 0.7
0.405 0.50 % Ineffective 3.1 0.4 0.3
% Harmful 1.2 0.3 0.1
0.305 0.50 % Ineffective 4.0 0.5 0.4
% Harmful 1.7 0.2 0.3
0.155 0.50 % Ineffective 4.5 0.4 0.5
% Harmful 2.7 0.1 0.1
Table 4: Results from Study 2 when susceptible proportion changes randomly.
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mean(θNP ) SD(θNP ) n=100 n=376 n=500
0.405 0.05 % Ineffective 0 0 0
% Harmful 0 0 0
0.305 0.05 % Ineffective 0 0 0
% Harmful 0 0 0
0.155 0.05 % Ineffective 8.3 6.1 4.7
% Harmful 0.2 0 0
0.405 0.10 % Ineffective 0.2 0 0.2
% Harmful 0 0 0.1
0.305 0.10 % Ineffective 1.9 0.6 1.3
% Harmful 0.2 0 0.1
0.155 0.10 % Ineffective 16.3 10.6 10.2
% Harmful 3.0 1.7 1.2
0.405 0.50 % Ineffective 6.6 2.5 1.8
% Harmful 4.3 0.8 1.2
0.305 0.50 % Ineffective 7.1 2.4 1.9
% Harmful 4.1 1.2 0.5
0.155 0.50 % Ineffective 8.2 2.7 1.7
% Harmful 4.9 0.9 0.9
Table 5: Results from Study 2 when susceptible proportion decreases steadily over
time.
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mean(θNP ) SD(θNP ) Best Easiest
0.405 0.05 % Ineffective 0 0
% Harmful 0 0
0.305 0.05 % Ineffective 0 0
% Harmful 0 0
0.155 0.05 % Ineffective 4.5 4.5
% Harmful 0 0
0.405 0.10 % Ineffective 0 0
% Harmful 0 0
0.305 0.10 % Ineffective 0.6 0.5
% Harmful 0 0
0.155 0.10 % Ineffective 6.0 6.0
% Harmful 1.0 1.2
0.405 0.50 % Ineffective 0.6 0.2
% Harmful 0.3 0.2
0.305 0.50 % Ineffective 0.5 0.2
% Harmful 0.1 0
0.155 0.50 % Ineffective 1.1 1.2
% Harmful 0.3 0.3
Table 6: Comparison of the rates of bio-creep when either 1) the approved product
with the best estimated treatment effect or 2) the one most likely to lead to the
approval of an ineffective therapy is chosen as the active control for subsequent
trials.
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Variance Model C I C I
mean(θNP ) SD(θNP ) Mean Shifts N N Y Y
0.405 0.05 % Ineffective 0 0 0.2 0.3
% Harmful 0 0 0 0
0.405 0.10 % Ineffective 0.2 0.2 1.5 3.6
% Harmful 0 0 0.6 1.5
0.405 0.50 % Ineffective 6.6 17.4 2.3 4.6
% Harmful 4.3 10.5 1.5 3.4
0.305 0.05 % Ineffective 0 0 23.3 44.0
% Harmful 0 0 12.7 28.2
0.305 0.10 % Ineffective 1.9 3.3 19.2 35.2
% Harmful 0.2 0.2 9.9 21.6
0.305 0.50 % Ineffective 7.1 18.5 3.1 8.5
% Harmful 4.1 11.7 2.0 5.4
0.155 0.05 % Ineffective 8.3 17.4 21.3 38.5
% Harmful 0.2 0.2 18.8 35.9
0.155 0.10 % Ineffective 16.3 30.7 23.3 41.9
% Harmful 3.0 7.9 15.6 33.0
0.155 0.50 % Ineffective 8.2 19.2 6.9 13.8
% Harmful 4.9 13.5 3.9 9.3
Table 7: Results of “Worse Case” Scenario Simulation. In each setting, the “sus-
ceptible” proportion decreases steadily from 0.95 in the first trial to 0.45 in the last
trial. Each trial stopped when 100 events had been observed.
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